Evidence map›Paper›PMID 27843149›Full record

ArticleMolecular psychiatry2018

JNK1 controls adult hippocampal neurogenesis and imposes cell-autonomous control of anxiety behaviour from the neurogenic niche.

H Mohammad, F Marchisella, S Ortega-Martinez, P Hollos, K Eerola, E Komulainen, N Kulesskaya, E Freemantle, V Fagerholm, E Savontaus and 4 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Molecular psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The mechanism of the JNK signaling pathway in drug addiction : Author list.Journal of molecular medicine (Berlin, Germany) · 2026
    Review
  5. DKK2 contributes to context discrimination and adult hippocampal neurogenesis by suppressing Wnt/PCP signaling.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Yomogin, Isolated fromAntioxidants (Basel, Switzerland) · 2022
    Article
  16. Article
  17. DualInternational journal of molecular sciences · 2021
    Article
  18. JNK Pathway in CNS Pathologies.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

H MohammadTurku Centre for Biotechnology, Åbo Akademi University and University of Turku, Turku, Finland.ORCID 0000-0002-5309-4034
F MarchisellaTurku Centre for Biotechnology, Åbo Akademi University and University of Turku, Turku, Finland.
S Ortega-MartinezTurku Centre for Biotechnology, Åbo Akademi University and University of Turku, Turku, Finland.
P HollosTurku Centre for Biotechnology, Åbo Akademi University and University of Turku, Turku, Finland.
K EerolaUniversity of Turku, Turku, Finland.
E KomulainenTurku Centre for Biotechnology, Åbo Akademi University and University of Turku, Turku, Finland.
N KulesskayaUniversity of Helsinki, Helsinki, Finland.
E FreemantleTurku Centre for Biotechnology, Åbo Akademi University and University of Turku, Turku, Finland.
V FagerholmTurku Centre for Biotechnology, Åbo Akademi University and University of Turku, Turku, Finland.
E SavontausUniversity of Turku, Turku, Finland.
H RauvalaUniversity of Helsinki, Helsinki, Finland.
B D PetersonNeuroplasticity and Behavior Unit, Laboratory of Neurosciences, National Institute on Aging, Baltimore, MD, USA.
H van PraagNeuroplasticity and Behavior Unit, Laboratory of Neurosciences, National Institute on Aging, Baltimore, MD, USA.ORCID 0000-0002-5727-434X
E T CoffeyTurku Centre for Biotechnology, Åbo Akademi University and University of Turku, Turku, Finland.
Åbo Akademi University · FINational Institute on Aging · USUniversity of Helsinki · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Promoting adult hippocampal neurogenesis is expected to induce neuroplastic changes that improve mood and alleviate anxiety. However, the underlying mechanisms remain largely unknown and the hypothesis itself is controversial. Here we show that mice lacking Jnk1, or c-Jun N-terminal kinase (JNK) inhibitor-treated mice, display increased neurogenesis in adult hippocampus characterized by enhanced cell proliferation and survival, and increased maturation in the ventral region. Correspondingly, anxiety behaviour is reduced in a battery of tests, except when neurogenesis is prevented by AraC treatment. Using engineered retroviruses, we show that exclusive inhibition of JNK in adult-born granule cells alleviates anxiety and reduces depressive-like behaviour. These data validate the neurogenesis hypothesis of anxiety. Moreover, they establish a causal role for JNK in the hippocampal neurogenic niche and anxiety behaviour, and advocate targeting of JNK as an avenue for novel therapies against affective disorders.

Indexed as

AffectAnimalsAnxietyAnxiety DisordersBehavior, AnimalCell ProliferationDepressionHippocampusMaleMiceMice, Inbred C57BLMice, KnockoutMitogen-Activated Protein Kinase 8NeurogenesisNeuronal PlasticityNeuronsMitogen-Activated Protein Kinase 8

Identifiers

PMID27843149
PMCPMC5794884
OpenAlexW2555461573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.